« Mixed Reviews of NY Hospitals in First DOH Infection Report | Main | Family of Deceased Psych Patient Will Sue »

Another context-the Pharmaceutical Business Review newsletter

For stargazers who visit Supra, here is a weekly publication I have found useful over time--it is grounded in business. The 'Business Digest' newsletter from the Pharmaceutical Business Review (1) published weekly, originates in the UK. With due respect to posting about it on the Supra blog as it is likely to be of interest and helpful to visitors by its nature, the newsletter contains unique content and is edited by Chris Eatough and it may be subscribed to (2). As one function of their other "Business Review" websites, it offers content that is produced by a dedicated team of journalists and global industry experts. In addition to the free content made available on the sites, an intelligence store ($$$) offers premium market analysis reports from the leading global suppliers of market research and industry analysis.
How is this related to the health care law? The newletters show a comprehensive and reliably current context on the subjects it covers-- legal references are sprinkled throughout. Invariably I would expect that you will find their 'Regulatory Developments' section interesting; it often focuses on the US Federal agencies. Or also, their 'Analyst's View',(about a page of reading sectioned into the newsletter itself) will contain US 'legal' material. For example, in this week's (July 8, 2008) 'Analyst's View' (reference to several Datamonitor reports from the intelligence store), they opine in part:

Following the controversy with Vioxx in 2004, US legislators were prompted to significantly expand the FDA's authority by passing the FDA Amendments Act of 2007. Although it is not yet certain to what extent the FDA will use its new powers, this crucial legislation changes the balance of power between pharmaceutical companies and the FDA, giving the agency greater powers to impose additional safety studies both prior to and post-approval. Thus, the legislation has the potential to increase development costs, reduce market penetration and impact upon approval rates. However, the new FDA power to demand post-marketing studies may actually be beneficial for certain drugs that would not be approved otherwise. Additionally, in recent years, the duration of clinical trials has increased so that, despite swifter approval times, the duration between the start of Phase I clinical trials and approval is becoming longer.

So I mention it here not for the purposes of advertising it, but because it can be especially useful to see what people, informed experts as well, are thinking from different perspectives who find/get different information, and so may ascertain the same or different trends that Supra readers may wish to know about.
This week's headliners include news on the AWP litigation and a potentially groundbreaking discovery in cancer treatment. (for a bit more of their news on this, click to below the fold)
(1)http://www.pharmaceutical-business-review.com/news.asp
(2)http://www.pharmaceutical-business-review.com/newsletters.asp

Excerpted from this week's newsletter:

Novartis Pharmaceuticals has announced that it will appeal a verdict in the Montgomery County Circuit Court, disputing the State of Alabama's claims that prices provided by the company to reporting services resulted in gross overpayment of physicians and doctors. The original lawsuit, filed in 2005, alleged that 79 pharmaceutical companies-including giants Novartis, GSK and AstraZeneca- knowingly reported inaccurate wholesale prices and acquisition costs to the state. If Novartis's appeal is unsuccessful, this week's ruling will mean that the company will be forced to pay $33 million in damages.
In more positive developments, a potentially groundbreaking discovery has been made in the field of cancer treatment. A drug discovered 20 years ago through the combination of focused nanotechnology and a fungus which contaminated the laboratory has this week been proven to be stunningly effective in the treatment of numerous types of cancer. Although it has yet to be tested in humans, the drug, dubbed lodamin, has the potential to become the basis for several future cancer treatments.

Post a comment

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)

About

This page contains a single entry from the blog posted on July 9, 2008 7:17 AM.

The previous post in this blog was Mixed Reviews of NY Hospitals in First DOH Infection Report.

The next post in this blog is Family of Deceased Psych Patient Will Sue.

Many more can be found on the main index page or by looking through the archives.